Swiss National Bank Chemo Centryx, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

Shares

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 09, 2022	BUY	$22.17 - $51.8 $68,727 - $160,580	3,100 Added 2.35%	135,100 $6.98 Million
Q2 2022 Aug 09, 2022	BUY	$15.36 - $27.51 $247,296 - $442,911	16,100 Added 13.89%	132,000 $3.27 Million
Q1 2022 May 09, 2022	BUY	$22.22 - $39.12 $182,204 - $320,784	8,200 Added 7.61%	115,900 $2.91 Million
Q4 2021 Feb 08, 2022	BUY	$18.38 - $40.5 $16,542 - $36,450	900 Added 0.84%	107,700 $3.92 Million
Q2 2021 Aug 06, 2021	SELL	$9.59 - $50.88 $37,401 - $198,432	-3,900 Reduced 3.52%	106,800 $1.43 Million
Q1 2021 May 07, 2021	BUY	$49.53 - $68.4 $84,201 - $116,280	1,700 Added 1.56%	110,700 $5.67 Million
Q4 2020 Feb 05, 2021	BUY	$47.25 - $65.16 $515,025 - $710,244	10,900 Added 11.11%	109,000 $6.75 Million
Q3 2020 Nov 09, 2020	BUY	$46.35 - $61.69 $324,450 - $431,830	7,000 Added 7.68%	98,100 $5.38 Million
Q2 2020 Aug 05, 2020	BUY	$38.58 - $65.07 $679,008 - $1.15 Million	17,600 Added 23.95%	91,100 $5.24 Million
Q1 2020 May 08, 2020	BUY	$32.73 - $50.78 $36,003 - $55,858	1,100 Added 1.52%	73,500 $2.95 Million
Q4 2019 Feb 06, 2020	BUY	$6.81 - $39.55 $122,580 - $711,900	18,000 Added 33.09%	72,400 $2.86 Million
Q3 2019 Nov 12, 2019	BUY	$6.47 - $8.96 $47,231 - $65,408	7,300 Added 15.5%	54,400 $369,000
Q2 2019 Aug 02, 2019	BUY	$8.31 - $14.85 $46,536 - $83,160	5,600 Added 13.49%	47,100 $438,000
Q1 2019 May 10, 2019	BUY	$10.01 - $13.89 $31,031 - $43,059	3,100 Added 8.07%	41,500 $576,000
Q2 2018 Aug 09, 2018	BUY	$10.62 - $13.98 $407,807 - $536,832	38,400 New	38,400 $506,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.